机构：[1]Department of Geriatrics, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, P.R. China[2]Chengdu Cancer Bioengineering Research Institute, Chengdu, P.R. China[3]Department of Oncology, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospitals, Chengdu, P.R. China四川省人民医院[4]Core Laboratory, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospitals, Chengdu, P.R. China四川省人民医院
Background. We previously reported a novel tumor-associated antigen with a molecular weight of approximately 48 kDa that was a fragment derived from human DNA-topoisomerase I. The aim of this study is to further investigate the clinical significance of the autoantibody in patients with non-small cell lung cancer (NSCLC). Methods. We determined serum levels of the autoantibody in 127 NSCLC patients, 127 age-, sex-, and smoking history-matched healthy control subjects, and 38 patients with pulmonary benign tumors by using a specific enzyme linked immunosorbent assay for the autoantibody. We then statistically evaluated its clinical application value. Results. Serum levels of the autoantibody in NSCLC patients were significantly higher than in healthy control subjects and patients with benign tumors (p = 0.001). The percentage of sera with a positive level of the autoantibody was 71.8%, 65.6%, 41.9%, and 48.0% in stages I, II, III, and IV of the cancer, respectively (p = 0.049). The area under the receiver-operating characteristics curve was 0.971 (95% confidence interval: 0.953 to 0988) for healthy controls and patients with benign tumors versus early stage NSCLC patients. Moreover, the overall survival rate of the patients in stages I, II, and IV with negative levels of the autoantibody was significantly lower than that of patients with positive levels of the autoantibody (p = 0.013, 0.023, and 0.047 for stages I, II, and IV, respectively). Conclusions. Our results indicate that the autoantibody can be used as a novel biomarker for the early diagnosis and prognosis of NSCLC. (C) 2018 by The Society of Thoracic Surgeons
基金：
This study was supported by grants from the Research and
Development Program of the Chengdu Technology Bureau
(no. KJXM20030826) that was awarded to Shang-mian Yie.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类|2 区医学
小类|2 区外科3 区心脏和心血管系统3 区呼吸系统
最新[2023]版：
大类|2 区医学
小类|2 区呼吸系统2 区外科3 区心脏和心血管系统
JCR分区：
出版当年[2018]版：
Q1SURGERYQ2RESPIRATORY SYSTEMQ2CARDIAC & CARDIOVASCULAR SYSTEMS
第一作者机构：[1]Department of Geriatrics, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, P.R. China[2]Chengdu Cancer Bioengineering Research Institute, Chengdu, P.R. China[3]Department of Oncology, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospitals, Chengdu, P.R. China[4]Core Laboratory, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospitals, Chengdu, P.R. China
通讯作者：
通讯机构：[1]Department of Geriatrics, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, P.R. China[2]Chengdu Cancer Bioengineering Research Institute, Chengdu, P.R. China[3]Department of Oncology, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospitals, Chengdu, P.R. China[4]Core Laboratory, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospitals, Chengdu, P.R. China[*1]Chengdu Cancer Bioengineering Research Institute, 37 Twelve Bridge Rd, Chengdu, Sichuan, P.R. China
推荐引用方式(GB/T 7714)：
Wen-bin Wu,Shang-mian Yie,Shang-rong Ye,et al.An Autoantibody Against Human DNA-Topoisomerase I Is a Novel Biomarker for Non-Small Cell Lung Cancer[J].ANNALS OF THORACIC SURGERY.2018,105(6):1664-1670.doi:10.1016/j.athoracsur.2018.01.036.
APA：
Wen-bin Wu,Shang-mian Yie,Shang-rong Ye,Ke Xie,Jian-bo Zhang...&Jia Zhang.(2018).An Autoantibody Against Human DNA-Topoisomerase I Is a Novel Biomarker for Non-Small Cell Lung Cancer.ANNALS OF THORACIC SURGERY,105,(6)
MLA：
Wen-bin Wu,et al."An Autoantibody Against Human DNA-Topoisomerase I Is a Novel Biomarker for Non-Small Cell Lung Cancer".ANNALS OF THORACIC SURGERY 105..6(2018):1664-1670
医学